Results 131 to 140 of about 4,043 (198)

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax. [PDF]

Leuk Res Rep, 2021
Siddiqui MT, Price A, Ferrajoli A, Borthakur G.   +3 more
europepmc   +1 more source

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. [PDF]

Blood Neoplasia
Kadia TM, Jain A, Rausch CR, Bataller A, Ravandi F, Jabbour E, Qiao W, Borthakur G, Short N, Montalban-Bravo G, Quesada AE, Burger J, Ferrajoli A, Wierda W, Hosing C, Kantarjian H.   +15 more
europepmc   +1 more source

Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study. [PDF]

Eur J Haematol, 2023
Crane JC, Gordon MJ, Basen-Engquist K, Ferrajoli A, Markofski MM, Lee CY, Fares S, Simpson RJ, LaVoy EC.   +8 more
europepmc   +1 more source

A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. [PDF]

Blood Adv, 2023
Gordon MJ, Duan Z, Zhao H, Nastoupil L, Ferrajoli A, Danilov AV, Giordano SH.   +6 more
europepmc   +1 more source

Late-Onset Depression in an Aging World: A Multidimensional Perspective on Risks, Mechanisms, and Treatment. [PDF]

Geriatrics (Basel)
D'Onofrio AM, Ferrajoli GF, Balzoni LM, Massetti M, Zanzarri A, Marano G, Mazza M, Koukopoulos A, Kotzalidis GD, Moccia L, Simonetti A, Janiri D, Di Nicola M, Sani G, Camardese G.   +14 more
europepmc   +1 more source

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD. [PDF]

Leukemia, 2023
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG.   +12 more
europepmc   +1 more source

El estilo de Letizia Gianformaggio

Doxa, 2004
Ferrajoli, Luigi
doaj   +1 more source

Decreased Transfusions in Premenopausal Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation Given Leuprolide According to an Abnormal Uterine Bleeding Algorithm. [PDF]

JCO Oncol Pract
Nebgen DR, Cheng L, Alousi AM, Ferrajoli A.   +3 more
europepmc   +1 more source

Gaetano Ferrajoli, Personenbeschreibung

, 2023
openaire   +1 more source

Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. [PDF]

Cancer
Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F.   +35 more
europepmc   +1 more source